期刊文献+

CA125及其半衰期监测进展期卵巢癌疗效和预后的意义 被引量:2

SIGNIFICANCE OF SERUM CA125 AND ITS HALF-LIFE IN MONITORING THE RESPONSE TO TREATMENT AND PROGNOSIS OF ADVANCED OVARIAN CANCER
下载PDF
导出
摘要 目的 :研究CA12 5及其半衰期监测进展期卵巢癌疗效及预后的应用价值。方法 :采用化学发光法测定 45例Ⅲ、Ⅳ期原发卵巢癌患者血浆CA12 5水平并计算CA12 5半衰期。结果 :45例患者治疗前血浆CA12 5水平均高于正常 ;采用单因素生存率时序检验 (Logranktest)分析表明 ,第 3次化疗后CA12 5水平、CA12 5半衰期及手术后残留灶大小、FIGO分期对预后有影响 (P值分别为 0 0 0 10、0 0 0 0 0、0 0 0 0 2、0 0 3 85 ) ;运用Cox风险回归模型进行多因素分析表明 :CA12 5半衰期对进展期卵巢癌患者有独立的预后价值 (χ2 =6 2 73 4,P =0 0 12 3 )。结论 :化疗早期CA12 5水平及其半衰期对进展期卵巢癌患者的预后评定有价值 ,检测该指标可及时发现耐药或复发 ,可及时给予相应的治疗措施。 Objective:To evaluate the value of serum CA125 and its half-life as a marker in monitoring the response to treatment and prognosis of advanced ovarian cancer.Method:Automated chemiluminescence system was used to detect the levels of serum CA125 in 45 stages Ⅲ and Ⅳ primary ovarian cancer patients.Result:①Pretreatment serum CA125 levels in 45 advanced ovarian cancer patients were significantly higher-than 35u/ml.②Univariate analysis shows statistical significance for survival for the following investigated variables:serum CA125 levels after the third cycle of chemotherapy?CA125 half-life and residual disease?FIGO stage(P=0 0010?0 0000?0 0002?0 0385,respectively).③In a survival analysis using the Cox proportional CA125 half-life calculation showed an independent prognostic significant(χ 2=6 2734,P=0 0123).Conclusion:This suggested CA125 levels of the early period of chemotherapy and serum half-life had earlier and more reliable value.If used clinically,it may help to find drug resitance or recurrence in time so as to take corresponding treating measures early.
出处 《江苏临床医学杂志》 2002年第4期340-342,共3页 Journal of Jiangsu Clinical Medicine
关键词 卵巢癌 CA125 半衰期 预后 化学发光法 ovarian cancer CA125 half-life prognosis
  • 相关文献

参考文献9

  • 1[1]Buller RE,Berman,M.L.Bloss,J.D.et al.CA125 regression:A model for epithelial ovarian cancer response[J].Am J Obestet Gynecol,1991;165:360
  • 2[2]Woolas RP, Xu FJ,Jacobs IJ,et al. Elevation of mutiple serum markers in patients with stage Ⅰovarian cancer[J].J Natl Cancer Inst,1993,85(21):1748
  • 3[3]Berek JS,Bast RC.Ovarian cancer screening.The use of serial complementary tumor markers to improve sensitivity and specificity for early detection[J].Cancer,1995,76(Suppl 10):2092
  • 4[4]Crombach G,Zipple HH,Wurz H.Clinical significance of cancer antigen 125 (CA125) in ovarian cancer[J].Cancer Detect Prev,1985,8(1-2):135
  • 5[5]Redman CWE, Bleckledge GR,Kelly K,et al. Early serum CA125 response and outcome in epithelial ovarian cancer[J].Eur Cancer,1990,26:593
  • 6[6]Mogensen O.Prognositc value of CA125 in advanced ovarian cancer[J].Gynecol Oncol,1992,44:207
  • 7[7]Colakovic S,Lukic V,Jelic S.et al.Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer[J].Int J Bio Markers,2000,15(2):147
  • 8[8]Yedema CA,Kenemans P,Voorhorst F,et al.CA125 half-life in ovarian cancer: A mutivariate survival analysis[J].Br J Cancer,1993,67:1631
  • 9[9]Hunter VJ,Daly L,Helms M,et al.The prognostic significance of CA125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoredution[J].Am J Obstet Gynecol,1990,163:1164

同被引文献22

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2Armstrong DK,Bundy B,Wenzel L,et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006,354( 1 ) : 34-43.
  • 3Barlin JN,Dao F,Bou Zgheib N,et aL Progression -free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperi- toneal cisplatin in ovarian,fallopian tufie,and pri mary peritoneal cancer[J]. Gynecol Oncol,2012, 125 (3) :621 - 624.
  • 4Buller RE1,Berrnan ML,Bloss JD,et al. CA 125 regres- sion:A model for epithelial ovarian cancer response[J]. Am J Obstet Gyneeol, 1991,165(2) -360-367.
  • 5Fujiwara K,Armstrong D, Morgan M,et al. Principles and practice of intraperitoneal chemotherapy for ovarian can- cer[J]. Int J Gynecol Cancer, 2007,17 ( 1 ) : 1-20.
  • 6Hess LM,Alberts DS. The role of intraperitoneal therapyin advanced ovarian cancer[J]. Oncology, 2007,21 (2) : 227- 232.
  • 7Prat A,Parera M,Peraha S,et al. Nadir CA-125 concen- tration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer[J]. Ann Oncol,2008,9(2) :327-331.
  • 8Juretzka MM, Barakat RR, Chi DS,et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolida- tion therapy[J]. Gynecol Oncol,2007,104(1 ): 176-180.
  • 9Rocconi RP,Matthews KS, Kemper MK,et al. The timing of normalization of CA-125 levels during primary chemother- apy is predictive of survival in patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2009, 114(2) : 242-245.
  • 10周慧梅,黄惠芳,潘凌亚,沈铿,吴鸣,杨佳欣,郎景和.血清CA125值的变化对判断上皮性卵巢癌疗效及预后的临床研究[J].中国实用妇科与产科杂志,2008,24(3):204-206. 被引量:35

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部